Authors

Srikanth Nagalla, MD, MS, is chief of Benign Hematology at Miami Cancer Institute and clinical professor of Medicine at Herbert Wertheim College of Medicine, Florida International University. Nagalla is a member of the American Society of Hematology’s Committee on Training and is co-director of the 2022 ASH Medical Educators Institute.

Adam C. Berger, MD, FACS, is the chief of melanoma and soft tissue surgical oncology at Rutgers Cancer Institute.

Sabrina Serani is the managing editor for Targeted Oncology, covering breast, lung, and brain cancers. Contact her at sserani@targetedonc.com.

Marco A. Ruiz Andia, M.D., MPH, FACP, FIDSA, is chief of HIV Oncology and HIV Stem Cell Transplantation at Miami Cancer Institute as well as an attending physician in the BMT unit. Dr. Ruiz is a medical oncologist specializing in the treatment of hematologic cancers, including leukemia, lymphoma, myelodysplastic syndrome and myelofibrosis, as well as cancer combined with human immunodeficiency virus (HIV). He is an associate professor at Florida International University’s Herbert Wertheim College of Medicine.

Idoroenyi Amanam, MD, is a hematologist-oncologist at City of Hope Comprehensive Cancer Center in Duarte, CA. Amanam obtained his medical degree from Meharry Medical College in Nashville, TN. He completed his training at St. Mary-UCLA Internal Medicine Residency. Following residency, Amanam completed his hematology and oncology training at the City of Hope/UCLA-Harbor combined program.